1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Eptinezumab
Trade Name:
Vyepti
Manufacturer/Distributor:
Lundbeck Canada Inc.
Classification:
Prevention of migraine; calcitonin gene-related peptide binding antibody
ATC Class:
N02CO05 - eptinezumab
Status:
active
Notice of Compliance (yyyy/mm/dd):
2021/01/11
Date Marketed in Canada (yyyy/mm/dd):
2021/01/11
Presentation:
Solution for infusion: 100 mg/mL. DIN: 02510839
Comments:
Infusion given every 12 weeks for prevention of migraines in patients who have at least 4 migraine days per month.
Source:
Product monograph
Back to:
Drug Product Listings 
